对奥利司他而言，脂肪痢是主要的胃肠道副反应。
For orlistat, steatorrhea produces the principal gastrointestinal side effects.
在考虑其可能存在某些毒副作用，美国食品药物管理局年初开始对在柜台里名为Alli，主要成份是奥利司他的减肥药进行调查，看它是否与那些肝损害案例有关。
The FDA began investigating orlistat, sold over the counter as Alli, and its potential links to liver damage earlier this year after concerns were raised about potentially harmful side effects.
目的探讨非酒精性脂肪性肝病(NAFLD)的发病机制及奥利司他结合低热量饮食治疗对NAFLD的有效性和安全性。
Objective To study the pathogenesis of non alcoholic fatty liver disease (NAFLD) and the efficacy and safety of Orlistat plus low caroli diet in the treatment of NAFLD.
应用推荐